Publications
84
Citations
5,309
Est. group size
—
Recurring co-author estimate
Active years
35
Publishing since 1992
Ellen B. Dennehy's work focuses on clinical research across several brain and metabolic conditions, including migraine treatment (lasmiditan), Alzheimer's disease progression and treatment (donanemab), bipolar disorder treatment patterns, and obstructive sleep apnea treatment outcomes (tirzepatide). Much of this research involves analyzing clinical trial data and patient-reported outcomes to understand treatment effectiveness and disease impact on daily functioning. This appears to be industry- or clinical-trial-affiliated research supporting the development and evaluation of pharmaceutical treatments.
Publication output has remained fairly steady over the past decade, fluctuating between 1 and 5 papers per year without a clear upward or downward trend, averaging under 3 papers per year in the most recent 5-year period.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Patients’ Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study
Patient · 2026
- Correlates of Functioning in Bipolar Disorder
Psychopharmacology Bulletin · 2025
- Concordance with Treatment Guidelines for Bipolar Disorder: Data from the Systematic Treatment Enhancement Program for Bipolar Disorder
Psychopharmacology Bulletin · 2025
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity
Sleep Medicine · 2025
- 2248 Clinical relevance of Donanemab treatment
Age and Ageing · 2024
- Clinical Relevance of Donanemab Treatment (S1.004)
Neurology · 2024
- Understanding the impact of slowing disease progression for individuals with biomarker-confirmed early symptomatic Alzheimer’s disease
Current Medical Research and Opinion · 2024
- Incremental declines in independence associated with disease progression in early symptomatic Alzheimer’s disease (AD)
Alzheimer s & Dementia · 2023
- Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
Neurology Clinical Practice · 2023
- Integrated Alzheimer’s Disease Rating Scale (iADRS): Clinically Meaningful Change Estimates (P6-3.004)
Neurology · 2022
- Migraine history and response to lasmiditan across racial and ethnic groups
Current Medical Research and Opinion · 2022
- Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain
Figshare · 2021
- A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Paediatric Patients with Migraine (1808)
Neurology · 2021
- Lasmiditan Efficacy in Mild Versus Moderate or Severe Migraine Headaches (1811)
Neurology · 2021
- Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain
Current Medical Research and Opinion · 2021
- Neurology×4
- Current Medical Research and Opinion×3
- Alzheimer s & Dementia×2
- Age and Ageing×2
- Psychopharmacology Bulletin×2
- Stephen M. Strakowski
Medicine · Indiana University
- J.R. Calabrese
Medicine · The Ohio State University
- Robert A. Kowatch
Medicine · The Ohio State University
- Eric A. Youngstrom
Medicine · The Ohio State University
- Mikael Landén
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile